Pulmonary Arterial Hypertension
About
-
Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.
Load morePulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.
PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.
Load Less
-
Sriram D Rao, Srinath Adusumalli, Jeremy A Mazurek, et alCardiac Failure Review 2020;6:e05.DOI: https://doi.org/10.15420/cfr.2019.09
-
Michela Faggioni, Domenico G Della Rocca, Sanghamitra Mohanty, et alCardiac Failure Review 2020;6:e04.DOI: https://doi.org/10.15420/cfr.2019.03
-
Hiroshi WatanabeEuropean Cardiology Review 2018;13(1):35–7.DOI: https://doi.org/10.15420/ecr.2017:22:2
-
Meshal Soni, Edo Y BiratiUS Cardiology Review 2018;12(1):8–12.DOI: https://doi.org/10.15420/usc.2017:21:1
